test

Since the discovery of monoclonal antibodies, they have been pursued as safer, more specific therapeutic options for patients.  While they have been validated in areas of cancer and infectious disease, all of these antibodies have been generated to a pre-determined target of interest, generated in mice and humanized or created from non-immune human V-gene libraries via phage display and taken through months of optimization.  North Coast believes that the best antibodies for therapeutic use would be those that we as humans generate via our in vivo immune responses to cancer and infectious disease.  By interrogating human IgG memory B-cells with North Coast technology (BLAST), it is possible to gain access to both current and historical antibodies generated against various disease-associated epitopes over the progression of diseases such as cancer and infectious disease and even autoimmunity.  In many cases the desired antibodies are rare within our repertoire.  The BLAST approach has been validated in finding common antibodies and those considered to be the equivalent of the proverbial “needle in the haystack”. 

Areas of Interest:

Basic Rationale: